Anlotinib Retrospective Study for Esophageal Cancer

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Esophageal Neoplasms Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Site

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Esophageal cancer diagnosed pathologically or clinically
Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion criteria

None

Treatment and study plan

Anlotinib

Drug

This is an observational study.

Primary outcomes

PFS

Time frame: From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Progression Free Survival

Secondary outcomes

OS

Time frame: From date of admission until the date of death from any cause, assessed up to 24 months

Overall Survival

Sponsors and collaborators

Lead sponsor

Feng Wang

Other

Registry information

Official study title

Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study

Important dates

Study start: 2019
Primary completion: 2022
Study completion: 2022
First posted: Mar 31, 2022
Registry last updated: Mar 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed